Cinacalcet

Limits on what this shows

• Key negative/null findings: No ATP or direct mitochondrial-function measurement was reported in the diabetic-kidney study; PGC-1α is a biogenesis marker, not a measurement of mitochondrial output.
• At-risk subgroups: Not established in humans; the endothelial toxicity signal has no established clinical correlate at approved dosing.
• Counter-evidence on record: The two tier B sources are, in effect, counter-evidence to each other on direction; neither has been replicated in humans or at clinically relevant exposures for the toxicity signal.

Regulatory status

Not addressed in labeling.

Population evidence

In vitro: mouse brain microvascular (bEND.3) endothelial cells exposed to cinacalcet 18-30 μM showed significant mitochondrial membrane depolarization and elevated caspase-9 at 30 μM (p<0.05), with growth arrest and near-complete cell death by 2 days; the effect was independent of calcium-sensing-receptor activation, suggesting direct cytotoxicity rather than the drug's intended pharmacology. In vivo: db/db diabetic mice given cinacalcet 10 mg/kg in diet for 12 weeks showed increased intrarenal PGC-1α (a mitochondrial biogenesis regulator) alongside reduced apoptosis (TUNEL-positive cells, p<0.01) in kidney tissue, an effect reversed by blocking intracellular calcium (BAPTA-AM), indicating a genuine calcium-sensing-receptor-dependent, protective pathway at a therapeutic-equivalent dose.

Mechanism

Named for both directions but distinct: the endothelial toxicity is receptor-independent and occurs only at supra-therapeutic concentrations (peak human plasma exposure at approved doses is far below 18 μM); the renal protective signal is receptor- and calcium-dependent, via CaMKKβ-LKB1-AMPK-PGC-1α signaling, at a dietary dose comparable to clinical use.

Counter-evidence held on record

Do not generalize the in vitro toxicity finding to clinical dosing; the concentrations used (18-30 μM) are well above typical human plasma exposure. This entry should not be used to claim either mitochondrial harm or mitochondrial benefit at approved doses in humans.

Limits on what this shows

• Key negative/null findings: Neither study used a placebo-treated comparator group followed in parallel (both are before/after or non-randomized designs), so regression to the mean, concurrent dialysis-technique changes, or other unmeasured confounders cannot be excluded. Calcium and phosphate were reported stable in study 2, arguing against confounding by acute mineral shifts.
• At-risk subgroups: Not applicable; this is a described benefit, not a risk, and is bounded to hemodialysis patients with secondary hyperparathyroidism specifically (not primary hyperparathyroidism or parathyroid carcinoma populations).
• Counter-evidence on record: Lack of randomized placebo control in both sources is the main limitation disclosed above; no study reviewed found cinacalcet worsening oxidative stress markers.

Regulatory status

Not addressed in regulatory labeling; both sources are independent investigator-led observational studies.

Population evidence

Study 1 (International Urology and Nephrology, 2014): 42 hemodialysis patients on cinacalcet 60 mg/day vs. 38 matched healthy controls, 6-month follow-up; malondialdehyde decreased, superoxide dismutase/paraoxonase/catalase/carbonic anhydrase/glutathione peroxidase activity increased, flow-mediated dilation improved; the 8-OHdG/dG oxidative-DNA-damage ratio trended down but was not clearly statistically significant. Study 2 (Nephron, 2018): 58 hemodialysis patients with sHPT (PTH >300 pg/mL), before/after 6 months; advanced oxidation protein products fell from 152 to 49 μmol/L (p<0.0001, ~68% reduction) and total antioxidant capacity (ImAnOx) rose from 260 to 272 μmol/L (p=0.04).

Mechanism

Partially named: in study 2, the change in antioxidant capacity correlated with cinacalcet dose (r=0.30-0.35, p≤0.02) but not with the change in PTH, suggesting an effect independent of PTH lowering, possibly a direct antioxidant property of the molecule or of reduced uremic/vascular inflammatory burden; the precise biochemical target is not established.

Counter-evidence held on record

This is a reverse-direction (protective) finding: cinacalcet appears to reduce oxidative stress markers in dialysis patients rather than causing an antioxidant deficit. It should never be presented as evidence that antioxidant supplementation is unnecessary or that cinacalcet substitutes for one; it is reported here only to prevent it being mis-cited elsewhere as a harm.

Limits on what this shows

• Why no grade: The dual condition for ungraded is met: a targeted Crossref API query for cinacalcet plus copper returned five cinacalcet-related regulatory documents and zero results mentioning copper; broad web searches across multiple phrasings (trace elements, serum copper, copper/zinc ratio) returned no drug-specific or class-level source; and no consumer nutrient-depletion claim naming copper for cinacalcet was located. Cinacalcet's pharmacokinetic profile (Step 1) also gives no plausible mechanism: it is not chelating, does not alter gastric pH meaningfully, and its hepatic CYP3A4/2D6/1A2 metabolism has no known copper-cofactor dependency. Access note: PubMed's search-listing pages, Europe PMC, and OpenAlex all returned rate-limit (429) errors when queried directly for this term during this review and could not be checked as an additional channel; this is disclosed as a tooling limitation, not treated as confirming the gap further.

Limits on what this shows

• Why no grade: The dual condition for ungraded is met: a Crossref API query for cinacalcet plus iron/ferritin returned no cinacalcet-related results among matches for iron metabolism generally; broad web searches (ferritin, transferrin, iron status) returned no drug-specific or class-level source. The erythropoietin-resistance literature (case report and unopened trial titles under Oxygen delivery/utilization) concerns red-cell production responsiveness, not ferritin, transferrin saturation, or other direct iron-status markers, so it was not used to support even a yellow grade here; conflating the two would double count one signal as two findings. Access note: PubMed search-listing pages, Europe PMC, and OpenAlex returned rate-limit (429) errors when queried directly for this term during this review; this is a disclosed tooling limitation, not a confirmed absence beyond what WebSearch and Crossref could show.

Limits on what this shows

• Key negative/null findings: None found; this is a genuine data gap on the microbiome-composition question specifically, distinguished from the GI-motility/secretion question, on which data does exist.
• At-risk subgroups: Not established.
• Counter-evidence on record: None found.

Regulatory status

Not addressed in labeling beyond the very high rate of nausea/vomiting (31%/27% vs. 19%/15% placebo in 6-month trials), which is a GI tolerability effect, not a microbiome finding.

Population evidence

Preclinical only. A JCI Insight study using human colonic T84 cells, CFTR-expressing FRT cells, human bronchial epithelial cells, and CD1 mice found cinacalcet (10-30 μM in vitro; 1-30 mg/kg intraperitoneal in vivo) inhibited forskolin-induced intestinal chloride secretion by ~50-85% (concentration-dependent, CaSR-dependent) and reduced cholera-toxin-induced fluid accumulation by ~75% (p<0.001) and heat-stable E. coli enterotoxin-induced fluid accumulation by ~60% (p<0.01) in mouse intestinal loops. No human trial has been conducted for this indication. A separate physiology review (drug named specifically for its action on gastric G-cell gastrin release) describes CaSR's broader role in gut fluid absorption, motility, and immune balance, proposing that CaSR-targeted agents could "condition the gut microenvironment," but reports no direct microbiome composition or diversity data for cinacalcet or any calcimimetic.

Mechanism

Present but indirect (mechanism class G, adjacent to microbiome disruption): altering luminal fluid secretion and epithelial ion transport could plausibly shift the gut microenvironment enough to affect microbial composition, but this has not been measured for cinacalcet.

Counter-evidence held on record

Do not present as evidence of microbiome disruption or protection; the preclinical data describe intestinal secretory physiology, not microbial composition, and no human microbiome study of cinacalcet exists.

Limits on what this shows

• Key negative/null findings: None found; this is a data-thinness limitation rather than a contradicting finding.
• At-risk subgroups: Not established beyond the severe-secondary-hyperparathyroidism-with-marrow-fibrosis population implied by the mechanism.
• Counter-evidence on record: None found; note this is an n=1 case report, which limits generalizability regardless of direction.

Regulatory status

Not addressed in labeling.

Population evidence

Directly opened: a single case report (Clinical and Experimental Nephrology) of a 62-year-old hemodialysis patient with recurrent secondary hyperparathyroidism (post-parathyroidectomy) started on cinacalcet 25 mg/day; intact PTH fell from 895 to 269 pg/mL and hemoglobin rose from 9.3 to 12.9 g/dL over 3 months, with the authors proposing that PTH reduction itself, independent of parathyroidectomy, improved erythropoiesis. Several other titles were found in search (e.g., comparative erythropoietin-resistance studies across calcitriol/cinacalcet/paricalcitol, and epoetin-dosage studies) that appear to point the same direction, but their full text could not be opened during this review (paywalled or bot-gated) and are not used as supporting evidence here beyond being listed in Sources.

Mechanism

Proposed, not fully established: severe secondary hyperparathyroidism is independently associated with bone marrow fibrosis and erythropoietin resistance; PTH lowering by any means (including parathyroidectomy) is associated with improved anemia parameters in the nephrology literature, and cinacalcet's core action is PTH lowering.

Counter-evidence held on record

Anemia in dialysis patients has many causes (iron status, erythropoietin dosing, inflammation, blood loss); do not attribute hemoglobin changes to cinacalcet without excluding these. This is a single-patient signal, not a population-level finding, and should never be used to suggest withholding iron or erythropoietin-stimulating-agent workups.

Limits on what this shows

• Key negative/null findings: No direct measurement of cellular ATP, oxygen consumption rate, or mitochondrial respiratory capacity was reported; per the tightened evidentiary standard for functional claims, a pathway marker moving is not the same as ATP production itself changing, and this entry is written and framed as unfalsifiable-as-ATP-claim without that direct measurement.
• At-risk subgroups: Not established in humans; this is a single-organ (kidney), single-disease-model (diabetic nephropathy) animal finding.
• Counter-evidence on record: None found; the gap is the absence of a direct energetic-output measurement, not a contradicting result.

Regulatory status

Not addressed in labeling.

Population evidence

C57BLKS/J db/db diabetic mice vs. db/m controls (n=8/group), cinacalcet 10 mg/kg in diet for 12 weeks: intrarenal CaMKKβ, phospho-LKB1, phospho-AMPK, and PGC-1α were all significantly increased (p<0.05 to p<0.01) in a calcium-dependent manner (reversed by BAPTA-AM), alongside improved autophagy markers (reduced beclin-1, reduced LC3-II/LC3-I ratio) and reduced apoptosis.

Mechanism

Named: CaSR-calcium-CaMKKβ-LKB1-AMPK-PGC-1α signaling is a well-characterized cellular energy-sensing pathway; PGC-1α specifically drives mitochondrial biogenesis, which is upstream of, but not equivalent to, ATP output.

Counter-evidence held on record

Do not present as evidence that cinacalcet increases cellular energy or ATP; the source measures upstream signaling and biogenesis markers in diabetic kidney tissue in mice, not ATP itself, and shares its origin with the Mitochondrial burden entry above (see Overlap map).